TS-ONE + cisplatin + everolimus

This is a combination therapy consisting of TS-ONE (likely tegafur/gimeracil/oteracil), cisplatin (a platinum-based chemotherapy agent), and RAD001 (everolimus). Everolimus (RAD001, brand names Afinitor, Zortress, Certican, Votubia) is an mTOR (mammalian target of rapamycin) inhibitor that works by blocking the activity of the mTOR protein. It is a derivative of sirolimus (rapamycin) and functions similarly as an mTOR inhibitor. Everolimus is used as an immunosuppressant to prevent organ transplant rejection and as a targeted therapy for various types of cancer. The mechanism of action involves inhibiting mTORC1 (mammalian target of rapamycin complex 1), which plays an essential role in protein synthesis downstream of the PI3K/AKT pathway that is dysregulated in many human cancers. By inhibiting mTOR, everolimus reduces cell proliferation, glycolysis, and angiogenesis in solid tumors. Since the search results don't provide specific information about the combination therapy "TS-ONE + cisplatin + RAD001" as a whole, it is inferred that this is likely a combination treatment regimen being studied or used for cancer treatment, possibly for advanced solid tumors.